Loading
Adipokines, Inflammation, and Metabolic Diseases / Regulation of Appetite and Obesity · Journal article
American Journal of Physiology-regulatory, Integrative and Comparative Physiology · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
In high-fat diet-fed mice, tirzepatide monotherapy reduced body weight and food intake; intermittent cold exposure increased acute energy expenditure and improved glucose homeostasis independent of weight change. Combined treatment showed no additive benefit over tirzepatide alone, contradicting the hypothesis that thermogenic activation would amplify weight loss. This negative preclinical finding requires validation and does not yet inform clinical practice.
Controlled factorial preclinical intervention study in inbred mice. Male and female C57BL/6J mice on high-fat diet for 8 weeks prior to randomisation. Intervention: Tirzepatide 10 nmol/kg plus intermittent cold exposure (4°C, 1 h/day, 5 days/week for 3 weeks). Compared with: Tirzepatide alone, cold exposure alone, and vehicle control (no tirzepatide, no cold exposure).
Tirzepatide (10 nmol/kg) reduced body weight, food intake, and adiposity in both male and female C57BL/6J mice Intermittent cold exposure (4°C, 1 h/day, 5 days/week) acutely increased energy expenditure and improved glucose homeostasis independent of weight loss Combined tirzepatide and intermittent cold exposure showed no additive effects on weight loss or metabolic parameters compared to tirzepatide alone
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This negative preclinical result suggests that combining tirzepatide with cold-induced thermogenesis may not yield synergistic weight-loss benefit in mice. Clinicians should await human trial evidence before considering cold exposure adjuncts to tirzepatide therapy.
Preclinical animal study testing a combination intervention hypothesis with negative primary outcome; results do not support additive benefit and require clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This negative preclinical result suggests that combining tirzepatide with cold-induced thermogenesis may not yield synergistic weight-loss benefit in mice. Clinicians should await human trial evidence before considering cold exposure adjuncts to tirzepatide therapy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity results from an imbalance between energy intake and energy expenditure. While pharmacological approaches such as tirzepatide, a dual GIP/GLP-1 receptor agonist, reduce food intake and body weight, enhancing energy expenditure via intermittent cold exposure–induced activation of thermogenesis may provide complementary benefits. Intermittent cold exposure increases energy expenditure and improves glucose homeostasis independent of weight loss. The objective of this study was to investigate the individual and combined effects of tirzepatide and intermittent cold exposure (ICE) on weight loss and glucose homeostasis. We hypothesized that combining ICE with tirzepatide would lead to greater weight loss and improvements in glucose homeostasis than tirzepatide alone. Male and female C57BL/6J mice were fed a high fat diet for 8 weeks and then treated with tirzepatide (10 nmol/kg) or vehicle and exposed, or not, to ICE (4°C, 1 h/day, 5 days/week) for 3 weeks. Body weight/composition, energy expenditure, food intake and glucose homeostasis were assessed. Tirzepatide reduced body weight, food intake, and adiposity in both sexes while ICE, acutely increased energy expenditure and improved glucose homeostasis independent of changes in body weight. There were no additive effects of combining tirzepatide and ICE. Our findings highlight that combining tirzepatide-mediated reduction in energy intake with ICE–induced activation of thermogenesis yields complementary, but not necessarily additive improvements in metabolic health.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.